Authors
Diarmuid D Sugrue, Orla Cullivan, Eoghan Cunnane, Niall Davis, Min Yuen Teo, Ivor Cullen
Published in
BJU international. Nov 03, 2026. Epub Nov 03, 2026.
Abstract
To determine the prevalence of programmed death ligand 1 (PD-L1) expression in penile squamous cell carcinoma (PSCC) and evaluate its associations with clinicopathological features and survival outcomes.
A systematic review was carried out using PubMed, the Excerpta Medica dataBASE (EMBASE), Scopus, Web of Science and Cochrane. Random-effects meta-analysis synthesised prevalence, hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS), and odds ratios (ORs) for lymph node metastases (LNM) and tumour characteristics. Meta-regression was caried out for pre-specified moderators.
A total of 16 studies (1634 patients) were included, with median follow-up of 44 months. The pooled PD-L1 prevalence was 53% (95% confidence interval [CI] 44-62%) with substantial between-study heterogeneity. PD-L1 positivity was associated with worse CSS (HR 1.94, 95% CI 1.54-2.44; P < 0.001) but not OS (HR 1.28, 95% CI 0.89-1.86; P = 0.2). PD-L1 positivity was associated with higher tumour stage (pathological T stage [pT]1 vs pT2-4, OR 1.67, 95% CI 1.22-2.29, P = 0.001), higher tumour grade (Grade 1 vs Grade 2-3, OR 2.60, 95% CI 1.94-3.5, P < 0.001), and LNM (OR 2.32, 95% CI 1.57-3.42, P < 0.001). Sensitivity testing and meta-regression did not materially alter pooled effects.
Programmed death ligand 1 is associated with adverse clinicopathological features and worse CSS in PSCC. Prospective validation is required to assess its independent prognostic value. Similarly PD-L1's predictive value for immunotherapy benefit cannot be determined from the current evidence and requires evaluation with treatment-specific prospective studies.
PMID:
42974892
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0